Clazakizumab: Difference between revisions
Content deleted Content added
Nominated for deletion; see Wikipedia:Articles for deletion/ALD518. (TW) |
m Moving from Category:Bristol Myers Squibb to Category:Drugs developed by Bristol Myers Squibb using Cat-a-lot |
||
| (114 intermediate revisions by 38 users not shown) | |||
| Line 1: | Line 1: | ||
{{Short description|Chemical compound}} |
|||
<!-- Please do not remove or change this AfD message until the issue is settled --> |
|||
{{AfDM|page=ALD518|logdate=2009 November 11|substed=yes|help=off}} |
|||
<!-- For administrator use only: {{oldafdfull|page=ALD518|date=11 November 2009|result='''keep'''}} --> |
|||
<!-- End of AfD message, feel free to edit beyond this point --> |
|||
{{drugbox |
{{drugbox |
||
| type |
| type = mab |
||
| mab_type = mab |
|||
| ⚫ | |||
| source |
| source = zu |
||
| target |
| target = [[Interleukin 6|IL6]] |
||
| |
| image = |
||
| alt = |
|||
| ⚫ | |||
| |
| caption = |
||
| |
| tradename = |
||
| |
| Drugs.com = |
||
| |
| MedlinePlus = |
||
| |
| pregnancy_AU = |
||
| |
| pregnancy_US = |
||
| ⚫ | |||
| ⚫ | |||
| |
| legal_AU = |
||
| ⚫ | |||
| ⚫ | |||
| |
| legal_UK = |
||
| |
| legal_US = |
||
| ⚫ | |||
| pregnancy_US = |
|||
| ⚫ | |||
| legal_AU = |
|||
| ⚫ | |||
| legal_UK = |
|||
| legal_US = |
|||
| ⚫ | |||
| routes_of_administration = infusion |
| routes_of_administration = infusion |
||
| bioavailability = |
|||
| ⚫ | |||
| metabolism = |
|||
| ⚫ | |||
| excretion = |
|||
| CAS_number = 1236278-28-6 |
|||
| UNII_Ref = {{fdacite|correct|FDA}} |
|||
| UNII = 4S38Z8RA9O |
|||
| ATCvet = |
|||
| ⚫ | |||
| ATC_suffix = |
|||
| PubChem = |
|||
| ChemSpiderID = none |
|||
| ⚫ | |||
| KEGG = D10312 |
|||
| C=6426 | H=9972 | N=1724 | O=2032 | S=42 |
|||
| synonyms = ALD518, BMS-945429 |
|||
}} |
}} |
||
'''ALD518''' a humanized [[monoclonal antibody]] against [[interleukin-6]]. |
|||
'''Clazakizumab''' (formerly '''ALD518''' and '''BMS-945429'''), an [[investigational drug]], is an [[aglycosylated]], humanized rabbit [[monoclonal antibody]] against [[interleukin-6]].<ref name="Handbook">{{cite book|title=Handbook of Therapeutic Antibodies, Volume 2|date=2007|publisher=Wiley Blackwell|page=987|isbn=9783527329373|url=https://books.google.com/books?id=svHsBQAAQBAJ&q=Clazakizumab,+BMS-945429+ALD518&pg=PA987|access-date=January 23, 2017}}</ref> Clazakizumab was developed by [[Bristol Myers Squib]] and [[Alder Biopharmaceuticals]]. A preliminary randomized, double-blind, [[placebo]]-controlled, [[phase 2 clinical trial|phase 2]] dose-ranging study of clazakizumab in [[psoriatic arthritis]] patients, funded by the manufacturer, suggested that clazakizumab may be an effective treatment option for musculoskeletal aspects of [[psoriatic arthritis]]; however, the antibody lacked a [[dose-response effect]].<ref name="ArthRheum1">{{cite journal|vauthors=Mease PJ, Gottlieb AB|display-authors=etal|title=The efficacy and safety of clazakizumab, an anti-interleukin-6 monoclonal antibody, in a phase IIb study of adults with active psoriatic arthritis.|journal=Arthritis Rheumatol|date=September 2016|volume=68|issue=9|pages=2163–73|doi=10.1002/art.39700|pmid=27059799|s2cid=3644962}}</ref> |
|||
==Clinical trials== |
|||
===Cancer=== |
|||
Phase II trial for advanced cancer.<ref>http://www.boliven.com/clinical_trial/NCT00866970</ref> |
|||
==See also== |
|||
===Rheumatoid arthritis=== |
|||
* [[Tocilizumab]] (Actemra) an anti-IL-6 receptor mAb |
|||
Phase II trial for [[rheumatoid arthritis]].<ref>http://clinicaltrials.gov/ct2/show/NCT00867516</ref> |
|||
* [[Anti-IL-6]], other anti-interleukin-6 agents |
|||
==References== |
==References== |
||
{{ |
{{Reflist}} |
||
{{Monoclonals for immune system}} |
|||
{{Interleukin receptor modulators}} |
|||
[[Category:Drugs developed by Bristol Myers Squibb]] |
|||
{{pharma-stub}} |
|||
[[Category:Antibodies]] |
|||
[[Category:Experimental monoclonal antibodies]] |
|||
Latest revision as of 07:01, 2 December 2023
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Humanized |
| Target | IL6 |
| Clinical data | |
| Other names | ALD518, BMS-945429 |
| Routes of administration | infusion |
| ATC code |
|
| Legal status | |
| Legal status |
|
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C6426H9972N1724O2032S42 |
| Molar mass | 145239.02 g·mol−1 |
Clazakizumab (formerly ALD518 and BMS-945429), an investigational drug, is an aglycosylated, humanized rabbit monoclonal antibody against interleukin-6.[1] Clazakizumab was developed by Bristol Myers Squib and Alder Biopharmaceuticals. A preliminary randomized, double-blind, placebo-controlled, phase 2 dose-ranging study of clazakizumab in psoriatic arthritis patients, funded by the manufacturer, suggested that clazakizumab may be an effective treatment option for musculoskeletal aspects of psoriatic arthritis; however, the antibody lacked a dose-response effect.[2]
See also
[edit]- Tocilizumab (Actemra) an anti-IL-6 receptor mAb
- Anti-IL-6, other anti-interleukin-6 agents
References
[edit]- ^ Handbook of Therapeutic Antibodies, Volume 2. Wiley Blackwell. 2007. p. 987. ISBN 9783527329373. Retrieved January 23, 2017.
- ^ Mease PJ, Gottlieb AB, et al. (September 2016). "The efficacy and safety of clazakizumab, an anti-interleukin-6 monoclonal antibody, in a phase IIb study of adults with active psoriatic arthritis". Arthritis Rheumatol. 68 (9): 2163–73. doi:10.1002/art.39700. PMID 27059799. S2CID 3644962.